These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 27312037)
21. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239 [TBL] [Abstract][Full Text] [Related]
22. Safety and quality outcomes in peritoneal surface malignancy patients: developing a national center for excellence in Colombia. Arias F; Herrera-Almario G; Pozo ME; Londoño-Schimmer E; Otero JM; Cardona A; Cortes N; Mora M Ann Surg Oncol; 2015 May; 22(5):1733-8. PubMed ID: 25239004 [TBL] [Abstract][Full Text] [Related]
23. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116 [TBL] [Abstract][Full Text] [Related]
24. Is advanced age a hesitation for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer? Cigdem Arslan N; Bisgin T; Altay C; Yavuzsen T; Karaoglu A; Canda AE; Sarioglu S; Sokmen S J BUON; 2018 Dec; 23(7):77-83. PubMed ID: 30722115 [TBL] [Abstract][Full Text] [Related]
25. Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients. Piso P; Nedelcut SD; Rau B; Königsrainer A; Glockzin G; Ströhlein MA; Hörbelt R; Pelz J Ann Surg Oncol; 2019 Jan; 26(1):148-154. PubMed ID: 30456672 [TBL] [Abstract][Full Text] [Related]
26. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study. Ye J; Ren Y; Wei Z; Peng J; Chen C; Song W; Tan M; He Y; Yuan Y Surg Oncol; 2018 Sep; 27(3):456-461. PubMed ID: 30217302 [TBL] [Abstract][Full Text] [Related]
27. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Votanopoulos KI; Russell G; Randle RW; Shen P; Stewart JH; Levine EA Ann Surg Oncol; 2015 Apr; 22(4):1274-9. PubMed ID: 25319583 [TBL] [Abstract][Full Text] [Related]
28. Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study. Hentzen JEKR; Rovers KP; Kuipers H; van der Plas WY; Been LB; Hoogwater FJH; van Ginkel RJ; Hemmer PHJ; van Dam GM; de Hingh IHJT; Kruijff S Ann Surg Oncol; 2019 Jul; 26(7):2210-2221. PubMed ID: 30877495 [TBL] [Abstract][Full Text] [Related]
29. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640 [TBL] [Abstract][Full Text] [Related]
30. Standard Operating Procedures for Anesthesia Management in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improve Patient Outcomes: A Patient Cohort Analysis. Fichmann D; Roth L; Raptis DA; Kajdi ME; Gertsch P; Vonlanthen R; de Rougemont O; Moral J; Beck-Schimmer B; Lehmann K Ann Surg Oncol; 2019 Oct; 26(11):3652-3662. PubMed ID: 31359273 [TBL] [Abstract][Full Text] [Related]
31. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases. Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033 [TBL] [Abstract][Full Text] [Related]
32. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer. Cornali T; Sammartino P; Kopanakis N; Christopoulou A; Framarino Dei Malatesta M; Efstathiou E; Spagnoli A; Ciardi A; Biacchi D; Spiliotis J Ann Surg Oncol; 2018 Mar; 25(3):679-687. PubMed ID: 29282600 [TBL] [Abstract][Full Text] [Related]
33. Outcomes in Peritoneal Dissemination from Signet Ring Cell Carcinoma of the Appendix Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Munoz-Zuluaga C; Sardi A; King MC; Nieroda C; Sittig M; MacDonald R; Gushchin V Ann Surg Oncol; 2019 Feb; 26(2):473-481. PubMed ID: 30523470 [TBL] [Abstract][Full Text] [Related]
34. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score. Malfroy S; Wallet F; Maucort-Boulch D; Chardonnal L; Sens N; Friggeri A; Passot G; Glehen O; Piriou V Surg Oncol; 2016 Mar; 25(1):6-15. PubMed ID: 26979635 [TBL] [Abstract][Full Text] [Related]
35. More Synchronous Peritoneal Disease but Longer Survival in Younger Patients with Carcinomatosis from Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Solomon D; DeNicola NL; Feferman Y; Bekhor E; Reppucci ML; Feingold D; Aycart SN; Magge DR; Golas BJ; Labow DM; Sarpel U Ann Surg Oncol; 2019 Mar; 26(3):845-851. PubMed ID: 30643994 [TBL] [Abstract][Full Text] [Related]
36. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients. Mercier F; Passot G; Villeneuve L; Levine EA; Yonemura Y; Goéré D; Sugarbaker PH; Marolho C; Bartlett DL; Glehen O; Ann Surg Oncol; 2018 Apr; 25(4):1094-1100. PubMed ID: 29238881 [TBL] [Abstract][Full Text] [Related]
37. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution. Teo MC; Tan GH; Tham CK; Lim C; Soo KC Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144 [TBL] [Abstract][Full Text] [Related]
38. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Votanopoulos KI; Sugarbaker P; Deraco M; Morris D; Glehen O; Elias D; De Simone M; Robella M; Heyd B; Kusamura S; Baratti D; Chouliaras K; Russell G; Shen P; Levine EA; Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418 [TBL] [Abstract][Full Text] [Related]
39. Outcomes of Cytoreductive Surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Votanopoulos KI; Newman NA; Russell G; Ihemelandu C; Shen P; Stewart JH; Levine EA Ann Surg Oncol; 2013 Oct; 20(11):3497-503. PubMed ID: 23780382 [TBL] [Abstract][Full Text] [Related]
40. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly. Huang Y; Alzahrani NA; Alzahrani SE; Zhao J; Liauw W; Morris DL World J Surg Oncol; 2015 Aug; 13():262. PubMed ID: 26311565 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]